1. Honrado ER, Tallo V, Balis AC, Chan GP, Cho SN Noncompliance with the world health organization-multidrug therapy among leprosy patients in Cebu, Philippines: its causes and implications on the leprosy control program. Dermatol Clin. 2008,26:221-229. 2. Ji B, Perani EG,Petinom C &Grosset JH. Bactericidal activities of Combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrobial Agents and Chemotherapy, 1996,40:393-399. 3. Banerjee DK,, McDermott-Lancaster RD& McKenzie S. Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. Antimicrobial agents and chemotherapy, 1997,41:b326-b330. 4. Ji B, Jamet P, Perani EG et al. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrobial Agents and chemotherapy, 1996,40:2137-2141. 5. World Health Organization. Implementing the stop TB strategy: A handbook for national tuberculosis control programmes. WHO/HTM/TB/2008.401 6. World Health Organization, Report on Third Meeting of the WHO Technical Advisory Group on Elimination of Leprosy .(WHO/CDS/CPE/CEE/2002.29),WHO, Geneva. 7. 沈建平,李文忠,周敏,等.麻风患者166例统一联合化疗后2年随访.中华皮肤科杂志,2010,43(43):75-78. 8. Kaur I, Dogra S, Kumar B, Radotra BD. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients. Int J Lepr Other Mycobact Dis. 2002,70:174-181. 9. Vara N, Marfatiya Y, A study on the impact of FD-MDT on 200 leprosy patients, Indian J Lepr. 2005,77:217-227. 10. Sales AM, Sabroza PC, da Costa Nery JA, Duppre NC, Sarno EN. A comparative study between 12 and 24-dose therapeutic regimens for multibacillary leprosy patients.Int J Lepr Other Mycobact Dis. 2004,72:320-323. 11. Kyaw KYAW, Tin Mg TSOH, San Yi Yi SWE, Yuzuru NAGAOKA, Shinichiro TAKEZAKI, Koichi SUZUKI, Norihisa ISHII. Clinical analysis of multibacillary leprosy patients after 1-year fixed world health organization recommended multidrug therapy at Yangon General Hospital, Myanmar.Jonrnal of Dermatology, 2008:35:264-269. 12. MF Balagon, RV Cellona and PR Saunderson. Type 2 (ENL) Reactions Observed in MB Patients with One Year and with Two Year WHO-MDT. Report of 17th International Leprosy Congress. 2008: 72. 12. Debol SM, Herron MJ, Nelson RDJ Leukoc Biol. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction.1997 Dec;62:827-836. 13. Suda T, Suzuki Y, Matsui T, Inoue T, Niide O, Yoshimaru T, Suzuki H, Ra C, Ochiai T. Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. Br J Dermatol. 2005 May;152:887-895. |